vs
Side-by-side financial comparison of Principal Financial Group (PFG) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $750.8M, roughly 3.0× Principal Financial Group). Zoetis runs the higher net margin — 26.6% vs 0.3%, a 26.3% gap on every dollar of revenue. On growth, Principal Financial Group posted the faster year-over-year revenue change (4.0% vs 2.9%). Over the past eight quarters, Zoetis's revenue compounded faster (-2.1% CAGR vs -58.3%).
Principal Financial GroupPFGEarnings & Financial Report
Principal Financial Group, Inc. (PFG) is an American global financial investment management and insurance company headquartered in Des Moines, Iowa, United States.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
PFG vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $750.8M | $2.3B |
| Net Profit | $1.9M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | — | — |
| Net Margin | 0.3% | 26.6% |
| Revenue YoY | 4.0% | 2.9% |
| Net Profit YoY | 783.0% | -0.2% |
| EPS (diluted) | — | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $750.8M | $2.3B | ||
| Q4 25 | $4.6B | $2.4B | ||
| Q3 25 | $3.7B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $3.7B | $2.2B | ||
| Q4 24 | $4.8B | $2.3B | ||
| Q3 24 | $3.0B | $2.4B | ||
| Q2 24 | $4.3B | $2.4B |
| Q1 26 | $1.9M | $601.0M | ||
| Q4 25 | $517.0M | $603.0M | ||
| Q3 25 | $213.8M | $721.0M | ||
| Q2 25 | $406.2M | $718.0M | ||
| Q1 25 | $48.1M | $631.0M | ||
| Q4 24 | $905.4M | $581.0M | ||
| Q3 24 | $-220.0M | $682.0M | ||
| Q2 24 | $353.1M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 33.0% |
| Q1 26 | 0.3% | 26.6% | ||
| Q4 25 | 11.3% | 25.3% | ||
| Q3 25 | 5.8% | 30.0% | ||
| Q2 25 | 11.1% | 29.2% | ||
| Q1 25 | 1.3% | 28.4% | ||
| Q4 24 | 19.1% | 25.1% | ||
| Q3 24 | -7.3% | 28.6% | ||
| Q2 24 | 8.2% | 26.4% |
| Q1 26 | — | $1.42 | ||
| Q4 25 | $2.30 | $1.37 | ||
| Q3 25 | $0.95 | $1.63 | ||
| Q2 25 | $1.79 | $1.61 | ||
| Q1 25 | $0.21 | $1.41 | ||
| Q4 24 | $3.92 | $1.29 | ||
| Q3 24 | $-0.95 | $1.50 | ||
| Q2 24 | $1.49 | $1.37 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PFG
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
